All In Biotech

Company

Boehringer Ingelheim

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Boehringer Ingelheim.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

54

28 still marketed

Novel approvals

21

Approvals since 2021

29

Originals and new uses

Phase 3 trials

392

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Hernexeos new use Breakthrough therapyPriority reviewFeb 26, 2026
  • Jascayd approved Breakthrough therapyPriority reviewOrphanDec 19, 2025
  • Jascayd approved NovelBreakthrough therapyPriority reviewOrphanOct 7, 2025
  • Hernexeos approved NovelBreakthrough therapyAccelerated approvalPriority reviewAug 8, 2025
  • Spevigo new use OrphanMay 28, 2025
  • Cyltezo new use May 20, 2025
  • Synjardy new use Mar 7, 2025
  • Synjardy Xr new use Mar 7, 2025
  • Cyltezo new use Apr 30, 2024
  • Spevigo new use Breakthrough therapyOrphanMar 18, 2024

Drugs in development (25)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

Recruiting Phase 3 trials

Largest first.

Marketed drugs (28)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.